Immunome Stock Surges on Positive Clinical Trial Results
Immunome shares rose 48% in three months after Phase 3 trial results for desmoid tumor drug Varegacestat showed 84% reduced progression risk. FDA approval sought in 2026.
Topic
Latest reporting and analysis tagged with desmoid tumors.
Immunome shares rose 48% in three months after Phase 3 trial results for desmoid tumor drug Varegacestat showed 84% reduced progression risk. FDA approval sought in 2026.